{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:22:43Z","timestamp":1790634163523,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.ejca.2015.12.029","type":"journal-article","created":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T00:30:19Z","timestamp":1454545819000},"page":"31-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours\u00a0in a real-life setting"],"prefix":"10.1016","volume":"57","author":[{"given":"St\u00e9phane","family":"Bouchet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Poulette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Titier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Lassalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelilah","family":"Abouelfath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chevreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Bompas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Collard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Duffaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Cupissol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Adenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Le Cesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binh","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Molimard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejca.2015.12.029_bib1","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/cncr.21419","article-title":"Gastrointestinal stromal tumor: 5 years later","volume":"104","author":"van der Zwan","year":"2005","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2015.12.029_bib2","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.5858\/2006-130-1466-GSTROM","article-title":"Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis","volume":"130","author":"Miettinen","year":"2006","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.ejca.2015.12.029_bib3","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/cncr.23199","article-title":"Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)","volume":"112","author":"Dematteo","year":"2008","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2015.12.029_bib4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(09)70242-6","article-title":"Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis","volume":"10","author":"Gold","year":"2009","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2015.12.029_bib5","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5350","key":"10.1016\/j.ejca.2015.12.029_bib6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.ejca.2015.12.029_bib7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2015.12.029_bib8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","article-title":"Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2015.12.029_bib9","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ejca.2005.04.034","article-title":"Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg","volume":"41","author":"Zalcberg","year":"2005","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2015.12.029_bib10","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ejca.2006.01.030","article-title":"KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours","volume":"42","author":"Debiec-Rychter","year":"2006","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2015.12.029_bib11","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejca.2015.12.029_bib12","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejca.2015.12.029_bib13","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/fcp.12007","article-title":"Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory","volume":"27","author":"Bouchet","year":"2013","journal-title":"Fundam Clin Pharmacol"},{"issue":"19","key":"10.1016\/j.ejca.2015.12.029_bib14","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","article-title":"Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2015.12.029_bib15","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1158\/1078-0432.CCR-12-0490","article-title":"A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients","volume":"18","author":"Eechoute","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2015.12.029_bib16","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"issue":"20 Pt 1","key":"10.1016\/j.ejca.2015.12.029_bib17","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-05-2596","article-title":"Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors","volume":"12","author":"Delbaldo","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2015.12.029_bib18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00280-004-0876-0","article-title":"Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group","volume":"55","author":"Judson","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10.1016\/j.ejca.2015.12.029_bib19","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2009.26.5785","article-title":"Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib","volume":"28","author":"Yoo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl. 15","key":"10.1016\/j.ejca.2015.12.029_bib20","first-page":"10564","article-title":"Trough imatinib plasma levels in patients treated for advanced gastrointestinal stromal tumors evidence of large interpatient variations under treatment with standard doses","volume":"26","author":"Bui","year":"2008","journal-title":"ASCO Meeting Abstracts"},{"issue":"4","key":"10.1016\/j.ejca.2015.12.029_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ctrv.2010.10.001","article-title":"Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?","volume":"37","author":"von Mehren","year":"2011","journal-title":"Cancer Treat Rev"},{"issue":"11\u201312","key":"10.1016\/j.ejca.2015.12.029_bib22","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cca.2011.02.023","article-title":"Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC\/MS-MS","volume":"412","author":"Bouchet","year":"2011","journal-title":"Clin Chim Acta"},{"issue":"24","key":"10.1016\/j.ejca.2015.12.029_bib23","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1200\/JCO.2008.21.3330","article-title":"Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial","volume":"27","author":"Le Cesne","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2015.12.029_bib24","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/bjc.2014.503","article-title":"Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma","volume":"111","author":"Suttle","year":"2014","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2015.12.029_bib25","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2015.12.029_bib26","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.ejca.2015.12.029_bib27","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/clpt.2010.186","article-title":"Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia","volume":"88","author":"Takahashi","year":"2010","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491600006X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491600006X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T01:58:20Z","timestamp":1654221500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491600006X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":27,"alternative-id":["S095980491600006X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.12.029","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours\u00a0in a real-life setting","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}